152 related articles for article (PubMed ID: 21406545)
1. Aggregated serum free light chains may prevent adequate removal by high cut-off haemodialysis.
Harding S; Provot F; Beuscart JB; Cook M; Bradwell AR; Stringer S; White D; Cockwell P; Hutchison CA
Nephrol Dial Transplant; 2011 Apr; 26(4):1438. PubMed ID: 21406545
[TBL] [Abstract][Full Text] [Related]
2. Online high-efficiency haemodiafiltration achieves higher serum free light chain removal than high-flux haemodialysis in multiple myeloma patients: preliminary quantitative study.
Granger Vallée A; Chenine L; Leray-Moragues H; Patrier L; Cognot C; Cartron G; Cristol JP; Canaud B
Nephrol Dial Transplant; 2011 Nov; 26(11):3627-33. PubMed ID: 21508098
[TBL] [Abstract][Full Text] [Related]
3. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
Hutchison CA; Plant T; Drayson M; Cockwell P; Kountouri M; Basnayake K; Harding S; Bradwell AR; Mead G
BMC Nephrol; 2008 Sep; 9():11. PubMed ID: 18808676
[TBL] [Abstract][Full Text] [Related]
4. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.
Hutchison CA; Heyne N; Airia P; Schindler R; Zickler D; Cook M; Cockwell P; Grima D
Nephrol Dial Transplant; 2012 Oct; 27(10):3823-8. PubMed ID: 22273664
[TBL] [Abstract][Full Text] [Related]
5. Treatment by long haemodialysis sessions with high cut-off filters in myeloma cast nephropathy: our experience.
Borrego-Hinojosa J; Pérez-del Barrio MP; Biechy-Baldan Mdel M; Merino-García E; Sánchez-Perales MC; García-Cortés MJ; Ocaña-Pérez E; Gutiérrez-Rivas P; Liébana-Cañada A
Nefrologia; 2013; 33(4):515-23. PubMed ID: 23897183
[TBL] [Abstract][Full Text] [Related]
6. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies.
Hutchison CA; Cockwell P; Reid S; Chandler K; Mead GP; Harrison J; Hattersley J; Evans ND; Chappell MJ; Cook M; Goehl H; Storr M; Bradwell AR
J Am Soc Nephrol; 2007 Mar; 18(3):886-95. PubMed ID: 17229909
[TBL] [Abstract][Full Text] [Related]
7. Extended high cut-off haemodialysis for myeloma cast nephropathy in Auckland, 2008-2012.
Tan J; Lam-Po-Tang M; Hutchison CA; de Zoysa JR
Nephrology (Carlton); 2014 Jul; 19(7):432-5. PubMed ID: 24931113
[TBL] [Abstract][Full Text] [Related]
8. Cast nephropathy with acute renal failure treated with high cut-off haemodialysis in a patient with multiple myeloma.
Shum HP; Chan KC; Chow CC; Kho BC; Yan WW
Hong Kong Med J; 2010 Dec; 16(6):489-92. PubMed ID: 21135429
[TBL] [Abstract][Full Text] [Related]
9. Management options for cast nephropathy in multiple myeloma.
Cockwell P; Hutchison CA
Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):550-5. PubMed ID: 20827195
[TBL] [Abstract][Full Text] [Related]
10. Haemodialysis using high cut-off dialysers for treating acute renal failure in multiple myeloma.
Martín-Reyes G; Toledo-Rojas R; Torres-de Rueda Á; Sola-Moyano E; Blanca-Martos L; Fuentes-Sánchez L; Martínez-Esteban MD; Díez-de los Ríos MJ; Bailén-García A; González-Molina M; García-González I
Nefrologia; 2012; 32(1):35-43. PubMed ID: 22294003
[TBL] [Abstract][Full Text] [Related]
11. Modelled cost-effectiveness of high cut-off haemodialysis compared to standard haemodialysis in the management of myeloma kidney.
Grima DT; Airia P; Attard C; Hutchison CA
Curr Med Res Opin; 2011 Feb; 27(2):383-91. PubMed ID: 21175375
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of the clinical relevance of serum measurements of free-light chains in patients with multiple myeloma].
Shimizu K; Itoh J; Sugiura I; Tsushita K; Kosugi H; Nagura E
Rinsho Ketsueki; 2006 Apr; 47(4):303-9. PubMed ID: 16715965
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy.
Hasegawa M; Kondo F; Yamamoto K; Murakami K; Tomita M; Nabeshima K; Nakai S; Kato M; Ohashi A; Arai J; Hiki Y; Ishii J; Emi N; Sugiyama S; Yuzawa Y
Ther Apher Dial; 2010 Oct; 14(5):451-6. PubMed ID: 21175542
[TBL] [Abstract][Full Text] [Related]
14. Effect of dialysis on serum/plasma levels of free immunoglobulin light chains in end-stage renal disease patients.
Cohen G; Rudnicki M; Schmaldienst S; Hörl WH
Nephrol Dial Transplant; 2002 May; 17(5):879-83. PubMed ID: 11981077
[TBL] [Abstract][Full Text] [Related]
15. The rationale and evidence base for the direct removal of serum-free light chains in the management of myeloma kidney.
Cockwell P; Cook M
Adv Chronic Kidney Dis; 2012 Sep; 19(5):324-32. PubMed ID: 22920643
[TBL] [Abstract][Full Text] [Related]
16. Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care.
Hutchison CA; Harding S; Mead G; Goehl H; Storr M; Bradwell A; Cockwell P
Artif Organs; 2008 Dec; 32(12):910-7. PubMed ID: 19133018
[TBL] [Abstract][Full Text] [Related]
17. Comparison of free light chain removal by four blood purification methods.
Kanayama K; Ohashi A; Hasegawa M; Kondo F; Yamamoto Y; Sasaki M; Hayashi H; Kato M; Hattori R; Yamashita H; Arai J; Ishii J; Emi N; Yuzawa Y
Ther Apher Dial; 2011 Aug; 15(4):394-9. PubMed ID: 21884475
[TBL] [Abstract][Full Text] [Related]
18. Serum free light chains for monitoring multiple myeloma.
Mead GP; Carr-Smith HD; Drayson MT; Morgan GJ; Child JA; Bradwell AR
Br J Haematol; 2004 Aug; 126(3):348-54. PubMed ID: 15257706
[TBL] [Abstract][Full Text] [Related]
19. High cut-off dialysis membranes: current uses and future potential.
Gondouin B; Hutchison CA
Adv Chronic Kidney Dis; 2011 May; 18(3):180-7. PubMed ID: 21531324
[TBL] [Abstract][Full Text] [Related]
20. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
